Abbott launches world's smallest rechargeable system with remote programming capabilities to treat movement disorders¹+

Liberta rc™ deep brain stimulation (dbs) system, recently approved by the u.s. fda, features neurosphere™ virtual clinic, which allows for remote programming of the system system offers the longest time between charges of any dbs technology on the market, allowing people with movement disorders to recharge the device only 10 times a year2* abbott park, ill., jan. 25, 2024 /prnewswire/ -- abbott (nyse: abt) announced today that it received approval from the u.s. food and drug administration (fda) to launch the liberta rc™ dbs system, the world's smallest rechargeable deep brain stimulation (dbs) device with remote programming, to treat people living with movement disorders.1 + the liberta rc dbs system also requires the fewest recharges of any fda-approved dbs system, needing only 10 recharge sessions a year for most people.2* communication between people and their doctors is critical to ensuring exceptional care, especially for those who suffer from chronic conditions, such as parkinson's disease and essential tremor, that can be treated with deep brain stimulation therapy.
ABT Ratings Summary
ABT Quant Ranking